Results 31 to 40 of about 50,051 (221)

Trends of influenza B during the 2010–2016 seasons in 2 regions of north and south Italy: The impact of the vaccine mismatch on influenza immunisation strategy [PDF]

, 2018
Influenza A and B viruses are responsible for respiratory infections, representing globally seasonal threats to human health. The 2 viral types often co-circulate and influenza B plays an important role in the spread of infection.
Alicino C., Ansaldi F., Calamusa G., Canepa P., Colomba G. M. E., Orsi A., Pojero F., Tramuto F., Trucchi C., Vitale F.   +9 more
core   +1 more source

MHC class I-presented T cell epitopes identified by immunoproteomics analysis are targets for a cross reactive influenza-specific T cell response. [PDF]

PLoS ONE, 2012
Influenza virus infection and the resulting complications are a significant global public health problem. Improving humoral immunity to influenza is the target of current conventional influenza vaccines, however, these are generally not cross-protective.
James S Testa, Vivekananda Shetty, Julie Hafner, Zacharie Nickens, Shivali Kamal, Gomathinayagam Sinnathamby, Ramila Philip   +6 more
doaj   +1 more source

The role of matrix protein 2 ectodomain in the development of universal influenza vaccines [PDF]

, 2019
The influenza A virus matrix protein 2 ectodomain (M2e) is a universal influenza A vaccine candidate. Numerous studies in laboratory mice, but very few in natural influenza A virus hosts, have demonstrated that M2e-based vaccines can provide protection ...
Saelens, Xavier
core   +1 more source

M2e-Based Influenza Vaccines with Nucleoprotein: A Review

Vaccines, 2021
Discovery of conserved antigens for universal influenza vaccines warrants solutions to a number of concerns pertinent to the currently licensed influenza vaccines, such as annual reformulation and mismatching with the circulating subtypes.
Mei Peng Tan, Wen Siang Tan, Noorjahan Banu Mohamed Alitheen, Wei Boon Yap   +3 more
doaj   +1 more source

End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17 [PDF]

, 2017
Introduction The United Kingdom is in the fourth season of introducing a universal childhood influenza vaccine programme. The 2016/17 season saw early influenza A(H3N2) virus circulation with care home outbreaks and increased excess mortality ...
Andrews, Nick, Correa, Ana, Cottrell, Simon, de Lusignan, Simon, Ellis, Joanna, Galiano, Monica, Gallagher, Naomh, Gunson, Rory, McMenamin, Jim, Moore, Catherine, Pebody, Richard, Potts, Alison, Reynolds, Arlene, Robertson, Chris, Sartaj, Muhammad, Sinnathamby, Mary, Thompson, Catherine, Warburton, Fiona, Yonova, Ivelina, Zambon, Maria   +19 more
core   +1 more source

Effectiveness of seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom : 2014/15 end of season results [PDF]

, 2015
The 2014/15 influenza season in the United Kingdom (UK) was characterised by circulation of predominantly antigenically and genetically drifted influenza A(H3N2) and B viruses.
Andrews, N., Cottrell, S., De Lusignan, S., Donati, M., Ellis, J., Galiano, M., Gallagher, N., Green, H., Gunson, R., Johnston, J., Marques, D., McMenamin, J., Moore, C., Mullett, D., Pathirannehelage, S., Pebody, R., Reynolds, A., Robertson, C., Thompson, C., Von Wissmann, B., Warburton, F., Yonova, I., Zambon, M.   +22 more
core   +1 more source

Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins

Vaccines, 2019
Vaccination is still the most efficient way to prevent an infection with influenza viruses. Nevertheless, existing commercial vaccines face serious limitations such as availability during epidemic outbreaks and their efficacy. Existing seasonal influenza
Seyed Davoud Jazayeri, Chit Laa Poh
doaj   +1 more source

An epitope-optimized human H3N2 influenza vaccine induces broadly protective immunity in mice and ferrets

npj Vaccines, 2022
There is a crucial need for an improved H3N2 influenza virus vaccine due to low vaccine efficacy rates and increased morbidity and mortality associated with H3N2-dominated influenza seasons.
Brianna L. Bullard, Jennifer DeBeauchamp, Matthew J. Pekarek, Erika Petro-Turnquist, Peter Vogel, Richard J. Webby, Eric A. Weaver   +6 more
doaj   +1 more source

The rise of companies from emerging markets in global health governance: opportunities and challenges [PDF]

, 2014
The article analyses the involvement of pharmaceutical companies from emerging markets in global health governance. It finds that they play a central role as low-cost suppliers of medicines and vaccines and, increasingly, new technologies.
ANNE ROEMER-MAHLER, Brooks, Brown, Buse, Chaudhuri, Clarke, Cooper Ramo, Drezner, Elbe, Fleury, Gold, Knight, Levy, Meyer, Petryna, Ramamurti, Roemer-Mahler, Schoofs, Wells, Whyte, Williams, Williamson, Youde, Zimmerman   +23 more
core   +1 more source

Long-lasting cross-protection against influenza A by neuraminidase and M2e-based immunization strategies [PDF]

, 2016
There is mounting evidence that in the absence of neutralizing antibodies cross-reactive T cells provide protection against pandemic influenza viruses. Here, we compared protection and CD8+ T cell responses following challenge with H1N1 2009 pandemic and
Callewaert, Nico, Fiers, Walter, Saelens, Xavier, Schepens, Bert, Schotsaert, Michael, Smet, Anouk, Stegalkina, Svetlana, Vanderschaeghe, Dieter, Vogel, Thorsten U, Ysenbaert, Tine   +9 more
core   +2 more sources